​Members of the House of Representatives urged the Centers for Medicare & Medicaid Services (CMS) to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. CMS has proposed to pay for separately payable, non pass-through drugs purchased through the 340B program at the average sales price minus 22.5 percent, rather than the current rate of ASP plus 6 percent.